What role does tumor type play in nivolumab dosing?

What dosing adjustments does tumor type require for nivolumab?

Nivolumab dosing follows a flat 240 mg every two weeks or 480 mg every four weeks for most adult patients. Tumor type does not trigger automatic dose changes.

What happens when nivolumab is combined with ipilimumab?

Some regimens pair nivolumab with ipilimumab. Tumor type determines whether those pairings occur and at what doses. Melanoma and renal cell carcinoma use 3 mg/kg nivolumab with 1 mg/kg ipilimumab every three weeks for four doses, then nivolumab alone. Non-small cell lung cancer uses 3 mg/kg nivolumab with 1 mg/kg ipilimumab every six weeks indefinitely. Colorectal cancer cases with microsatellite instability-high or mismatch repair-deficient tumors receive 3 mg/kg nivolumab with 1 mg/kg ipilimumab every three weeks for four doses, then nivolumab alone.

What dosing options exist for pediatric patients?

Pediatric patients receive weight-based dosing at 3 mg/kg every two weeks or 6 mg/kg every four weeks. Tumor type does not alter that rule.

How does tumor type influence patient monitoring?

Patients with certain tumor types require tighter monitoring. Melanoma patients need frequent skin examinations because of higher skin-related side effects. Renal cell carcinoma patients need kidney function tracking. Non-small cell lung cancer patients focus on lung function and respiratory symptoms.